甲磺酸培高利特治疗原发性帕金森病  

THE EFFICACY OF PERGOLIDE MESYLATE IN THE TREATMENT OF PARKINSON’S DISEASE

作　　者：张瑞珠[1] 张本恕[1] 程焱[1] 萧爱缨 李庆有[1] 黄恩强[1] 梁立平[1] 江德华[1] 

机构地区：[1]天津医科大学总医院神经内科

出　　处：《中国新药杂志》1997年第6期401-403,共3页Chinese Journal of New Drugs

摘　　要：采用随机双盲给药法观察６０例帕金森病患者，其中培高利特治疗组３０例，安慰剂对照组３０例，开放给药组６５例。结果显示：治疗组及开放给药组与安慰剂组疗效有差异（Ｐ＜０．０５），具有统计学意义。开放受试药组治疗前后功能缺损评分对照有显著差异（Ｐ＜０．０１），副作用的发生率仅为９．２％。对肝肾功能无损害，对血象及心脏功能亦无影响。The study was conducted on 60 parkinsonians.They were randomly,equally divided into active and control groups.Besides,another 65 patients with the disease were observed in an open trial.Results indicated that there is a significant difference in efficacy between active and control groups,and there is a significant difference in functional deficiency score of pre and post treatment in the open trial group.The incidence of ADRs is 9.2% without influences on liver ,renal and cardiac functions.

关 键 词：帕金森氏病 甲磺酸培高利特 药物疗法 

分 类 号：R742.505[医药卫生—神经病学与精神病学]